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Cystatins as Calpain Inhibitors: Engineered Chicken
Cystatin - and Stefin B-Kininogen Domain 2 Hybrids
Support a Cystatin-Like Mode of Interaction with the
Catalytic Subunit of m-Calpain
pose that (i) cystatin-type calpain inhibitors interact
with the active site of the catalytic domain of calpain
in a similar cystatin-like mode as with papain and (ii)
the potential for calpain inhibition is due to specific
subsites within the papain-binding regions of the
general cystatin fold.
Key words: Calpastatin /Kininogen/Papain /Stefin B/
Surface plasmon resonance/Temporary inhibition.
Introduction
The two ubiquitous calpains, m-calpain and m-calpain,
are intracellular, Ca2+-dependent cysteine proteinases
that have been implicated in many important cellular
functions and various pathologies (see Sorimachi et al.,
1997; Carafoli and Molinari, 1998; Suzuki and Sorimachi,
1998 for recent reviews). They consist of distinct (yet ho-
mologous) large (L-)subunits (80 kDa) und a common
small (S-)subunit (30 kDa). On the basis of sequence com-
parisons, the L-subunit has been predicted to contain
four and the S-subunit two domains. Whereas the catalyt-
ic domain (domain II) of the L-subunit shows a weak se-
quence homology to papain, both the L-subunit and the
S-subunit contain a Ca2+-binding calmodulin-like domain
(CaMLD). Until recently, only three-dimensional struc-
tures of the L-CaMLD were known (Blanchard et al., 1997;
Lin et al., 1997), and hypotheses on the molecular mecha-
nisms of activation and inhibition of calpains have been
contradictory. Meanwhile, two groups have published
crystal structures of the Ca2+-free, inactive form of m-cal-
pain, revealing the molecular architecture of this multido-
main protein (Hosfield et al., 1999; Strobl et al., 2000). In
these structures, the catalytic domain (II) appears disrupt-
ed into two subdomains (IIa and IIb), explaining the inac-
tivity of calpain in the absence of calcium. Activation
should involve a ‘fusion’ of the two subdomains, leading
to a functional papain-like catalytic domain (Hosfield et
al., 1999; Strobl et al., 2000). As long as the structure of a
Ca2+-activated calpain is not known, a number of ques-
tions concerning the molecular mechanisms of interac-
tion with substrates and inhibitors remain open.
Ca2+-activated m- and m-calpain are controlled by a
very specific intracellular protein inhibitor, calpastatin.
Calpastatin contains four repeats of the inhibitory unit,
each of which can inhibit calpain independently, but is
not able to inhibit other cysteine proteinases of the pa-
pain superfamily (Maki et al ., 1987; Emori et al ., 1988).
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Within the cystatin superfamily, only kininogen do-
main 2 (KD2) is able to inhibit m- and m-calpain. In an
attempt to elucidate the structural requirements of
cystatins for calpain inhibition, we constructed re-
combinant hybrids of human stefin B (an intracellular
family 1 cystatin) with KD2 and DL110 deletion mu-
tants of chicken cystatin-KD2 hybrids. Substitution of
the N-terminal contact region of stefinB by the corre-
sponding KD2 sequence resulted in a calpain in-
hibitor of K i = 188 nM. Deletion of L110, which forms a
b-bulge in family 1 and 2 cystatins but is lacking in
KD2, improved inhibition of m-calpain 4- to 8-fold. All
engineered cystatins were temporary inhibitors of
calpain due to slow substrate-like cleavage of a sin-
gle peptide bond corresponding to Gly9-Ala10 in
chicken cystatin. Biomolecular interaction analysis
revealed that, unlike calpastatin, the cystatin-type in-
hibitors do not bind to the calmodulin-like domain of
the small subunit of calpain, and their interaction with
the m-calpain heterodimer is completely prevented by
a synthetic peptide comprising subdomain B of cal-
pastatin domain 1. Based on these results we pro-
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Conversely, calpain is not inhibited by most cystatins
(Crawford, 1987), the only exceptions being the kinino-
gens. The second cystatin-like kininogen domain (KD2)
was shown to be responsible for calpain inhibition
(Salvesen et al., 1986). Whereas the interaction of calpain
with calpastatin has been studied in some detail (Takano
et al., 1995), the interaction between calpains and kinino-
gens remains to be investigated.
No relation can be found between cystatins and cal-
pastatin on the basis of sequence homology. They pos-
sess a well defined three-dimensional structure (Turk and
Bode, 1991), in contrast to the proposed disordered
structure of calpastatin domains (Uemori et al., 1990).
While attempting to identify the structural requirements
for calpain inhibition by cystatins, we have shown earlier
that substitution of the three chicken cystatin contact re-
gions (N-terminal trunk, first and second hairpin loop) by
the corresponding KD2 sequences in a single and com-
bined manner resulted in up to 1000-fold improved cal-
pain inhibition (Auerswald et al., 1996). However, inhibi-
tion of m-calpain by these chimeric proteins was found to
be temporary. In the present work, we investigate the
mechanism of temporary inhibition of m -calpain by chick-
en cystatin-KD2 hybrids and the potential reasons for it.
The second disulphide loop (Cys95-Cys115) of chicken
cystatin is extended by one leucine residue (L110) as
compared to the corresponding sequence in KD2 (see
Figure 1); L110 forms a b -bulge of the terminal b -sheet
that is conserved in family 1 and 2 cystatins (Bode et al.,
1988; Stubbs et al., 1990). This difference could be re-
sponsible for non-optimal binding of the chicken cys-
tatin-KD2 hybrids to calpain resulting in temporary inhibi-
tion. In order to test our hypothesis we constructed
chicken cystatin-KD2 D L110 deletion mutants and com-
pared them with the corresponding full-length chicken
cystatin-KD2 hybrids. 
Furthermore, we attempt to clarify whether calpain in-
hibition by engineered cystatins requires a family 2 (chick-
en cystatin) scaffold or is rather due to the presence of
calpain-binding sequences (as in KD2) on any cystatin
fold. For this purpose we constructed cystatin-KD2 hy-
brids using as parent molecule a member of family 1 of the
cystatin superfamily, human stefin B. Like all family 1
members, stefin B conserves the general architecture of
cystatins but, in contrast to chicken cystatin or KD2, oc-
curs intracellularly and lacks disulphide bridges. Stefin B
has a shorter N-terminal ‘trunk’ and a wider second hair-
pin loop than chicken cystatin (Stubbs et al., 1990).
The interaction of the chimeric inhibitors with human
m -calpain and with a recombinant fragment of its small
subunit was studied by real time biomolecular interaction
analysis using surface plasmon resonance technology. A
hypothesis is presented on the mode of interaction of
calpain with cystatin-type protein inhibitors and is com-
pared with the present knowledge on its interaction with
calpastatin.
Results
Gene Design for the Chimeric Proteins
Figure 1 shows the amino acid sequences of the engi-
neered proteins compared with those of the parent pro-
teins. The D Leu110 chicken cystatin-KD2 hybrids were
prepared from the corresponding chicken cystatin-KD2
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Fig. 1 Scheme of the Chicken Cystatin- and Stefin B-Kininogen Domain 2 Hybrids.
The contact regions of stefin B and chicken cystatin with papain (c1, c2, c3) were substituted by the corresponding sequences of human
kininogen domain 2 (grey) in a single and combined manner (hybrids sc1, sc3, sc1/2, sc1/3, sc1/2/3). cc, natural chicken cystatin; rcc, re-
combinant chicken cystatin (AEF-[M1, I 2 9 , L89] chicken cystatin); KD2, kininogen domain 2; SB, natural stefin B; rSB, recombinant stefin
B; D L110, Leu110 deletion mutant of cc. The sequences of chicken cystatin and stefin B were aligned according to topological equivalence
in tertiary structure (Stubbs et al., 1990). The peptide bonds cleaved during temporary inhibition of m -calpain are marked by arro w h e a d s .
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hybrids described earlier (Auerswald et al., 1996) by PCR
mutagenesis and ligated into the expression vector
pIN-III-ompA2 to allow periplasmic expression in E. coli.
The stefin B-KD2 hybrids were constructed following the
same general strategy as described previously for the
chicken cystatin-KD2 hybrids (Auerswald et al., 1996).
Three stefin B-KD2 hybrids were designed, carrying the
putative contact regions c1 (N-terminus) and c3 (second
hairpin loop) of KD2 in a single and combined manner.
Since contact region c2 (first hairpin loop) of stefin B and
KD2 are identical, further substitutions were not neces-
sary. A synthetic gene for stefinB (Figure 2) was designed
and assembled from twelve oligonucleotides according
to the method of Khorana (1979). The single cysteine
residue in stefin B (Cys3) was substituted by serine in or-
der to avoid dimerisation via disulphide bridges. The hy-
brids were then constructed either by total gene synthe-
sis or by cassette mutagenesis (see Materials and
Methods for details). The insertion of an EcoRI restriction
site at the 5’ end of the genes for ligation into the cloning
and expression vectors (pUC 18 and pASK 40) involved
the introduction of the tripeptide sequence Ala-Asn-Ser-
(ANS-) at the N-terminus of the recombinant proteins.
Cys124 and Cys127 of the N-terminal KD2 sequence
were replaced by Ser and Ala, respectively. Subcloning of
the genes into the expression vector pASK 40 enabled
periplasmic expression. 
Protein Expression, Purification and
Characterisation
The D Leu110 chicken cystatin-KD2 hybrids were isolated
from the periplasmic fractions of the induced E. coli cul-
tures and purified to 90– 95% homogeneity by affinity
chromatography on a carboxymethyl-papain Sepharose
column followed by anionic exchange chromatography
on a Mono Q column (Figure 3). The identity of the
chimeric proteins was verified by N-terminal amino acid
sequencing and mass spectrometry. Table 1 summarises
the results of expression, purification and characterisa-
tion of the hybrids.
The stefin B-KD2 hybrid SBsc1-KD2 (see Figure 1 for
explanation of abbreviations) was detected in mg
amounts (estimated by Western blotting and papain in-
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Fig. 2 Synthetic Gene Encoding Human Stefin B.
The upper panel shows the construction of the synthetic gene from 12 individual oligonucleotides (numbered lines) and the distribution
of unique restriction sites. The complete DNA and amino acid sequences of ANS-[C3S]-r-stefin B are presented in the lower panel.
Fig. 3 SDS-PAGE of the Purified Hybrids.
Lanes 1,5,7 show low molecular mass standards. Three to five
m g of purified inhibitors were applied: lane 2, D L110cc; lane 3,
D L110ccsc1/2-KD2; lane 4, D L110ccsc1/2/3-KD2; lane 6,
D L110ccsc2/3-KD2 and lane 8, SBsc1-KD2.
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hibitory activity) in the periplasm, whereas SBsc3-KD2
and SBsc1/3-KD2 formed inclusion bodies. The hybrid
SBsc1-KD2 was purified to 95% homogeneity and char-
acterised by SDS-PAGE (see Figure 3), reversed-phase
HPLC (data not shown), N-terminal amino acid sequenc-
ing and mass spectrometry (Table 1).
Inhibitory Profiles of the Hybrids
The equilibrium dissociation constants (Ki) as well as the
association and dissociation rate constants (kon, koff) of
the complexes formed between the inhibitors and differ-
ent cysteine proteinases are summarised in Table 2. In-
hibition of papain and cathepsin L by the chicken cys-
tatin hybrids was marginally less than that of the parent
molecules; nevertheless, all hybrids remained tight-
binding inhibitors of these enzymes (Ki in the pM range),
suggesting that neither deletion of the Leu110 residue in
the chicken cystatin hybrids nor the N-terminal substitu-
tion of stefin B with a KD2 sequence had essentially al-
tered the general cystatin fold required for tight-binding
interactions. On the other hand, deletion of Leu110 in
the chicken cystatin hybrids resulted in a 4-5-fold im-
provement of calpain inhibition. While the Ki of recombi-
nant stefin B for the inhibition of m -calpain is at least 60
m M, substitution of its N-terminus by that of KD2 in the
SBsc1-KD2 hybrid resulted in 300-fold improved calpain
inhibition (Ki=188 nM).
Temporary Inhibition of m-Calpain
Inhibition of m -calpain by the D L110 chicken cystatin-
KD2 and stefin B-KD2 hybrids was shown to be tempo-
rary. After rapid initial inhibition, the activity of calpain
reappeared and increased slowly until a second stable
equilibrium was reached. Figure 4 shows a typical inhibi-
tion experiment of m -calpain by D L110ccsc1/2-KD2.
The time course of the inhibition experiment can be ex-
plained by a conversion of the inhibitor into a ‘modified’
form of much lower affinity. This putative conversion was
confirmed by SDS-PAGE and N-terminal amino acid se-
quencing (Figure 5). After incubation of the hybrids
ccD L110sc1/2-KD2 and SBsc1-KD2 with m -calpain, a
second band was detected migrating at a lower apparent
100 B. García Díaz et al.
Table 1 Expression, Purification and Protein Chemical Characterisation of the D L110 Chicken
Cystatin-KD2 and Stefin B-KD2 Hybrids.
Hybrida Expression Purification N-terminal sequence Molecular mass
[mg/l]b [mg/l]b [Da]
D L110cc 3.5 1.6 AEFME >95% 13386.1
D L110ccsc1/2-KD2 3.2 1.6 AEF >95% 13865.9
D L110ccsc2/3-KD2 0.8 0.3 AEF >95% 13327.0
D L110ccsc1/2/3-KD2 2.0 0.8 AEFMAEG >90% 13838.7
SBsc1-KD2 5.5 1.5 ANSAEGPV >95% 12379.7
aSee Figures 1 and 6 for abbreviations.
bmg of active inhibitor per litre of E. coli cell culture.
Table 2 Equilibrium Dissociation Constants (Ki) and Rate Constants (kon, koff) of the Complexes of the Inhibitors with Different Cysteine
Proteinases.
Inhibitora Papain Cathepsin L m -Calpain
kon koff Ki kon koff Ki Ki
(M– 1s– 1) (s– 1) (nM) (M– 1s– 1) (s– 1) (nM) (nM)
r-chicken cystatin 1.3 x 107b 1.8 x 10– 5b 0.0014b 7.8 x 107b 6.7 x 10– 5b 0.0009b 75000
D L110cc 2.8 x 107 1.3 x 10– 4 0.0046 5.5 x 107 3.5 x 10– 4 0.0064 920*
ccsc1/2-KD2 3.2 x 107b 4.1 x 10– 5b 0.0013b 6.3 x 107b 3.3 x 10– 4b 0.0052b 127*
D L110ccsc1/2-KD2 2.9 x 107 9.7 x 10– 5 0.0034 2.5 x 107 3.7 x 10– 4 0.0148 29*
ccsc2/3-KD2 1.9 x 107b 6.3 x 10– 5b 0.0033b 4.0 x 107b 1.6 x 10– 4b 0.0040b ³ 30000
D L110ccsc2/3-KD2 4.5 x 106 1.1 x 10– 4 0.0244 1.3 x 107 2.8 x 10– 4 0.0215 ³ 5000
ccsc1/2/3-KD2 5.8 x 106b 2.8 x 10– 4b 0.0480b 3.9 x 106b 1.7 x 10– 3b 0.436b, * 380*
D L110ccsc1/2/3-KD2 2.9 x 106 2.0 x 10– 4 0.0690 2.8 x 106 1.2 x 10– 3 0.428* 100*
KD2 prot 7.3 x 106b 1.2 x 10– 4b 0.0160b 2.2 x 107b 3.3 x 10– 4b 0.0150b 5.4
L-kininogen 2.0 x 107b 6.4 x 10– 5b 0.0032b 3.0 x 107b 1.1 x 10– 4b 0.0035b 1.0
SBsc1-KD2 6.6 x 106 7.6 x 10– 5 0.0120 4.0 x 106 4.1 x 10– 5 0.0104 188*
r-stefin B 8.9 x 106 5.7 x 10– 5 0.0064 2.1 x 107 1.8 x 10– 4 0.0086 ³ 60000
a See Figures 1 and 6 for abbreviations.
b Data taken from Auerswald et al. (1996).
* Temporary inhibition.
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molecular mass. N-terminal sequencing of the incubated
mixtures revealed that the conversion is due to cleavage
of a single peptide bond, Gly18-Cys19 in the chicken
cystatin-KD2 hybrid, and Gly17-Ala18 in the stefinB-KD2
hybrid. These bonds correspond to Gly9-Ala10 in natural
chicken cystatin and Gly4-Ala5 in natural stefin B (see
Figure 1) involving the Gly residue that is highly con-
served within the cystatin superfamily (Turk and Bode,
1991).
Biomolecular Interaction Analysis
The chicken cystatin-KD2 hybrid ccD L110sc1/2-KD2and
the stefin B-KD2 hybrid SBsc1-KD2 were chosen to in-
vestigate the binding of m -calpain to these cystatin-like in-
hibitors and to compare it with the binding of m -calpain to
recombinant inhibitory calpastatin domain 1 (rCD1; Emori
et al., 1988). For real-time biomolecular interaction analy-
sis the inhibitors were immobilised on CM5 chips via
amino groups. The interaction of m -calpain with the immo-
bilised inhibitors was analysed in the presence and in the
absence of calcium. In the presence of 0.2 mM CaCl2 we
observed a strong binding of m -calpain to rCD1; but also
KD2prot (KD2 obtained by limited proteolysis of L-kinino-
gen) as well as the D L110chicken cystatin-KD2 and stefin
B-KD2 hybrids were able to bind the injected m -calpain
(Figure 6A). In contrast, Ca2+-activated calpain did not
bind to immobilised chicken cystatin or stefin B, which
were used as negative controls. When m -calpain was in-
jected in the absence of calcium, no binding to the immo-
bilised inhibitors was observed (data not shown).
Calpastatin peptide B (CPB), a synthetic peptide of 27
amino acids comprising the minimal inhibiting unit of cal-
pastatin domain 1, has been shown to be a competitive
inhibitor and is thus supposed to bind to the active site of
calpain (Maki et al ., 1988; Kawasaki et al., 1989; Craw-
ford et al., 1993). Therefore we performed competition
experiments with this peptide. For complex formation,
CPB was added to Ca2+-activated m -calpain (0.2 mM Ca2+
for 5 min) in a molar ratio of 20:1. When the mixture was
passed over the chips, only immobilised rCD1 was able
to bind m -calpain, whereas the immobilised chicken cys-
tatin-KD2 and stefin B-KD2 hybrids as well as KD2prot did
not display any binding (Figure 6 B). Similarly, binding of
m -calpain to the cystatin-like inhibitors was completely
abolished when the activated enzyme was pre-incubated
with an excess of whole rCD1 (data not shown). 
It has been shown previously that the inhibitory do-
main 1 of calpastatin is able to bind the calmodulin-like
domains of the large subunit (domain IV) and of the small
subunit (domain VI) of calpain (Takano et al., 1995).
Therefore we investigated the interaction of KD2 as well
as of cystatin- and stefin B-KD2 hybrids with a recombi-
nant 21 kDa fragment containing the complete CaMLD
(domain VI) of the small subunit (Figure 6C). Clearly, nei-
ther immobilised KD2 nor the immobilised chicken cys-
tatin-KD2 and stefinB-KD2 hybrids were able to bind the
21kDa protein. In contrast, immobilised rCD1 exhibited a
fast, strong interaction with this calpain fragment. Imme-
diately after the described binding experiments, the im-
mobilised inhibitors were able to bind again activated
calpain and carboxymethylated papain (data not shown),
proving their integrity and the validity of the results ob-
tained.
Discussion
Due to the lack of structural information on Ca2+-activat-
ed calpain and KD2, the precise molecular mechanism of
their interaction is still unknown. However, from a se-
quence alignment of KD2 with other members of the cys-
tatin superfamily and from its inhibitory profile (Auerswald
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Fig. 4 Temporary Inhibition of m -Calpain by D L110ccsc1/2-
KD2.
Typical inhibition experiment showing the time course of con-
centration of the fluorescent reaction product (AMC, circles) and
the reaction rate (triangles) calculated within a moving window of
10 min (v). After a constant reaction rate (v0) had been obtained
with m -calpain (10 nM), D L110ccsc1/2-KD2 (280 nM) was added
(arrow).
Fig. 5 Analysis of Temporary Inhibition by SDS-PAGE.
D L110ccsc1/2-KD2 (left) and SBsc1-KD2 (right) were incubated
with m -calpain for 90 min. Samples taken at time 0 (lane 2) and
90 min (lane 3) were analysed by SDS PAGE and N-terminal se-
quencing. The new sequences found were CVVP… for
D L110ccsc1/2-KD2 and AVSA… for SBsc1-KD2, resulting from
cleavage behind Gly18 or Gly17, respectively (see Figure 1 for
the complete sequences). Lane 1, low molecular mass stan-
dards.
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et al., 1996) we expect kininogen domain 2 to have a cys-
tatin-like structure and thus to inhibit calpain by a similar
molecular mechanism as it inhibits papain-like cysteine
proteinases. Moreover, structural alignment of the cat-
alytic domain (subdomains IIa and IIb) of m-calpain with
papain suggested that the functional active site formed
after calcium-triggered conformational changes should
be similar to the active site of papain (Hosfield et al.,
1999; Strobl et al., 2000). 
Exchange of the papain-binding regions of chicken
cystatin by the corresponding sequences of KD2 ren-
dered chicken cystatin-KD2 hybrids that inhibited m-cal-
pain with equilibrium dissociation constants (Ki) in the
higher nM range (Auerswald et al ., 1996). In contrast to
earlier results (Bradford et al., 1993), a contribution of all
three binding regions of the cystatins to calpain inhibition
could be demonstrated (Auerswald et al., 1996), leading
us to the hypothesis that the interaction between KD2
and calpain closely resembles the interaction of cystatins
with papain-like cysteine proteinases. Our results ob-
tained with the stefin B-KD2 hybrid SBsc1-KD2 support
this hypothesis. Stefin B belongs to family 1 of the cys-
tatin superfamily (Turk and Bode, 1991) and differs from
chicken cystatin (family 2) and KD2 (family 3) by its intra-
cellular occurrence and lack of disulphide bridges. Its
binding mode to cysteine proteinases is well document-
ed by the crystal structure of a stefinB complex with car-
boxymethylated papain (Stubbs et al., 1990). In the pres-
ent work, substitution of the N-terminal segment of
stefin B by the corresponding sequence of KD2 resulted
in a m -calpain inhibitor with a Ki of 188 nM, suggesting
that calpain inhibition is not dependent on the individual
scaffold of kininogen domain 2 or chicken cystatin, but is
rather due to the presence of calpain-binding sites which
may be located within the contact regions of either a fam-
ily 1, family 2 or family 3 cystatin-fold. As the two Cys
residues of the N-terminal segment of KD2 were replaced
by Ser and Ala in the SBsc1-KD2 hybrid, the N-terminal
‘small’ disulphide loop of KD2 seems to be no absolute
requirement for calpain inhibition. The corresponding
D L110ccsc1/2-KD2 hybrid containing these two cys-
teines is an only 6-fold more potent calpain inhibitor.
Examination of the inhibition profiles of the hybrids
against papain and cathepsin L (Table 2) reveals that the
102 B. García Díaz et al.
Fig. 6 Binding of m -Calpain to Immobilised Cystatin- und Calpastatin-Type Inhibitors.
Overlay plots of typical BIAcore sensorgrams showing the interaction of the immobilised inhibitors with injected m -calpain (A, B) and a
recombinant fragment (r-21 kDa) of its small subunit (C), respectively, in the presence of calcium ions. A preincubated mixture of Ca2+-
activated m -calpain and calpastatin peptide B (CPB) was injected in competition experiments (B). The panels on the left side show sen-
sorgrams obtained with a chip loaded with recombinant calpastatin domain 1 (rCD1, ——), kininogen domain 2 obtained by limited pro-
teolysis (KD2prot, –·–), and D L110ccsc1/2-KD2 (·····). On the right side, sensorgrams of a second chip loaded with rCD1 (——) and
SBsc1-KD2 (·····) are displayed. Arrowheads indicate start (left) and end (right) of injections. The ‘bulk’ effect of buffer constituents was
minimised by subtracting blank sensorgrams (not shown) obtained with immobilised chicken cystatin (left panels) or recombinant stefin
B (right panels).
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chimeric inhibitors inhibit these enzymes almost as effi-
ciently as the parent molecules. This allows us to assume
that the mutations did not significantly affect the general
cystatin-like mode of interaction with papain-like cys-
teine proteinases, although they introduced the addition-
al capability for calpain inhibition. The precise nature of
the sequences required for calpain inhibition cannot be
deduced from the limited number of hybrid proteins stud-
ied in this work, but the N-terminal contact region seems
to play a predominant role. New reports on cystatin C and
D have indeed shown that the N-terminal regions of cys-
tatins are the most important determinants of inhibitory
selectivity for individual papain-like proteinases (Mason
et al., 1998). On the other hand, changes within the cys-
tatin framework have been found to modulate inhibitory
specificity and potency (Gerhartz et al., 1997; Hall et al.,
1998). The latter observations are in accordance with our
findings that deletion of the single Leu110 residue in the
chicken cystatin-KD2 hybrids improved calpain inhibition
4 to 8-fold (see Table 2). Surprisingly, the very weak but
significant m -calpain inhibition by wild-type chicken (Ki =
75 m M) increased even 80-fold after deletion of L110.
Leu110 is not part of a contact region, but its deletion
was expected to amend the misannealing of the putative
c3 loop of KD2 to the chicken cystatin scaffold (Auer-
swald et al., 1996). 
In contrast to the stable inhibition of calpain by KD2, it
was found previously that all calpain-inhibiting chicken
cystatin-KD2 hybrids were temporary inhibitors (Auer-
swald et al., 1996). In the present work we were able to
show that this temporary inhibition is due to selective
cleavage of a single peptide bond after the conserved Gly
residue within the proposed N-terminal binding regions of
the chimeric inhibitors (corresponding to Gly9 in chicken
cystatin and Gly4 in stefin B), resulting in N-terminally
truncated inhibitors of much lower affinity. We have ob-
served cleavage of the Gly9-Ala10 peptide bond by pa-
pain in previous work with deletion mutants of the first and
second hairpin loop of chicken cystatin and explained it
by substrate-like cleavage of the mutated inhibitors due
to distorted binding in one of the two hairpin loop regions
required for the formation of a stable complex (Auerswald
et al., 1995; Machleidt et al., 1995). The fact that the re-
combinant chimeric calpain inhibitors, but not inhibitorily
active KD2 (obtained by limited proteolysis of L-kinino-
gen), are cleaved by calpain at the corresponding peptide
bond allows three conclusions: (i) the cystatin-type cal-
pain inhibitors interact with the active site of the catalytic
subunit of calpain; (ii) their mode of interaction with cal-
pain is similar to that of cystatins with papain-like cysteine
proteinases; (iii) in contrast to natural KD2, the chimeric
inhibitors fit imperfectly to the active site of calpain and
are therefore slowly cleaved in a substrate-like manner.
Attempts to generate permanent calpain inhibitors by
modification of the cleavage site do not seem promising
because mutations in the corresponding region of cys-
tatin C have been shown to decrease its binding affinity
for various cysteine proteinases (Björk et al., 1995).
Our initial hypothesis that the misalignment of the sec-
ond disulphide loop of chicken cystatin with the corre-
sponding part of KD2 might be responsible for the tem-
porary calpain inhibition of the chicken cystatin-KD2
hybrids was not confirmed. Although calpain inhibition by
all cc-KD2 D L110 deletion mutants was slightly improved
(see above), they remained temporary inhibitors. Like the
chicken cystatin-KD2 hybrids, the stefin B-KD2 hybrid
SBsc1-KD2 is also a temporary inhibitor of m -calpain. Se-
quence alignment of contact region c3 of stefin B with the
corresponding KD2 region displays even greater differ-
ences than in the case of chicken cystatin. This may ex-
plain why the hybrids SBsc3-KD2 and SBsc1/3-KD2
were not expressed as soluble proteins in E. coliperiplas-
mic fractions, but appeared as inclusion bodies in the cy-
toplasm. The second hairpin loop region appears to play
an important role in the maintenance of the overall
three-dimensional structure.
For the first time, the binding of whole heterodimeric
m -calpain to kininogen domain 2 and to calpain-inhibiting
recombinant cystatin variants was investigated by real
time biomolecular interaction analysis and compared
with the binding of m -calpain to the inhibitory domain 1 of
calpastatin. The most stringently conserved residues
among the four repetitive calpastatin domains are not
randomly distributed but cluster in three subdomains
designated A, B and C within each domain (Maki et al.,
1989). Structure-function analysis has revealed that re-
gion B is essential for inhibition and that a 27-residue
synthetic oligopeptide (calpastatin peptide B, CPB) com-
prising this region retains inhibitory activity in the low
nanomolar range. In this work, we were able to show by
real-time biomolecular interaction analysis that binding of
m -calpain to kininogen domain 2 as well as to
chicken cystatin-KD2 and stefin B-KD2 hybrids can be
prevented by an excess of CPB. Competition of CPB with
calpain substrates has been demonstrated previously by
kinetic analysis using calpastatin fragments containing
the region B (Maki et al., 1988; Kawasaki et al., 1989).
Binding of peptide B near the catalytic centre of calpain
has further been supported by competition experiments
using small inhibitors (Kawasaki et al., 1989; Crawford et
al., 1993). Based on these earlier reports, our results
strongly support the hypothesis that the cystatin-like in-
hibitors bind to the catalytic domain of calpain. 
Conversely, binding of m -calpain to recombinant cal-
pastatin domain 1 could not be prevented by CPB, indi-
cating that additional binding sites are involved. These
results agree with previously published BIAcore experi-
ments demonstrating that non-inhibitory peptides de-
rived from regions A and C of the calpastatin domain are
able to bind the calmodulin-like domains of the large and
of the small subunit of calpain, respectively (Takano et al.,
1995). CaMLD binding and the degree of calpain inhibi-
tion have been demonstrated to be well correlated (Ma et
al., 1994). Thus the tripartite subdomain structure of the
inhibitory calpastatin domain (regions A, B and C) should
contribute to the formation of a tight calpain-calpastatin
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complex (Takano et al., 1995). Neither kininogen domain
2 nor the chicken cystatin-KD2 and stefin B-KD2 hybrids
contain putative calmodulin-binding motifs. Accordingly,
we found that only calpastatin domain 1 but not the cys-
tatin-type inhibitors were able to interact with the S-
CaMLD of the 21 kDa fragment. 
Although the interaction of cystatins with papain-like
enzymes involves three main contact regions, these are
known to form a wedge-like contiguous contact area
binding to spatially closely related primed and non-
primed subsites of the enzymes (Bode et al., 1988). In
contrast, the proposed tripartite nature of the calpas-
tatin-calpain interaction would require simultaneous
binding to the active site in domain IIa+IIb as well as to
both CaMLDs (domain IV and domain VI) located quite far
apart from it (Hosfield et al., 1999; Strobl et al., 2000). So-
lution of the three-dimensional structures of calpain com-
plexes with calpastatin domains and kininogen domain 2
remains a challenge for future investigations.
Materials and Methods
Materials
All chemicals used were purchased from Sigma (Deisenhofen,
Germany), Merck (Darmstadt, Germany), Serva (Heidelberg,
Germany) or Fluka (Buchs, Switzerland) and were of analytical
grade. Restriction endonucleases and DNA modifying enzymes
were from Roche Molecular Biochemicals (Mannheim, Germany)
and New England Biolabs (Schwalbach, Germany). Human
kininogen domain 2 obtained by limited proteolysis of human L-
kininogen (Auerswald et al., 1996) was a generous gift from J.
Brzin (Ljubljana, Slovenia). Recombinant human calpastatin do-
main 1 and calpastatin peptide B (calpain inhibitor peptide) were
purchased from Calbiochem (Bad Soden, Germany) and Sigma,
respectively. Papain (EC 3.4.22.2) from Boehringer (Mannheim,
Germany) was repurified and active-site titrated with E-64 as de-
scribed previously (Barrett and Kirschke, 1981; Machleidt et al.,
1995). Human cathepsin L (EC 3.4.22.15) and human L -kinino-
gen were purchased from Calbiochem. Fluorogenic substrates
Z-Phe-Arg-AMC, Bz-Arg-AMC and Suc-Leu-Tyr-AMC were ob-
tained from Bachem (Heidelberg, Germany). All reagents and
materials for biomolecular interaction analysis were from Bia-
core AB (Uppsala, Sweden).
PCR Mutagenesis and Expression of D Leu 110 Chicken
Cystatin-KD2Hybrids
Plasmids containing the genes for chicken cystatin r-cc and
chicken cystatin-KD2 hybrids cc sc1/2-KD2, cc sc2/3-KD2 and
cc sc1/2/3-KD2 (Auerswald et al., 1996) were used for construc-
tion of the corresponding D Leu 110-variants. The D Leu 110
chicken cystatin-KD2 hybrids were prepared by PCR mutagen-
esis using these plasmids as templates and the oligonucleotide
primers CCD L110FO(5’-TGCACTGCAGGTTGAAATCGGTC-3’),
CC D L110RE (5’-CCGCTCGAGTTTGATCTGGTTCAGCCACGG-
3’), and SC3 D L110RE (5’-CCGCTCGAGTTTAGCGATACGCAG-
CTGGAT-3’). The PCR products were ligated into the expression
vector pIN-III-ompA2 after digestion with EcoRI and BamHI.
Correct plasmids were selected after restriction analysis and
DNA sequencing.
Synthesis, Cloning, Cassette Mutagenesis and Expression
of Human StefinB and Stefin B-KD2 Hybrids
A synthetic gene for stefin B was designed using the GCG pro-
gramme (HUSAR, Heidelberg, Germany) for editing DNA and
amino acid sequences (Figure 2). The cDNA sequence for
stefin B from GenBank (#LO3558) served as a scaffold for de-
sign. Whenever possible, codons present in highly expressed
genes of E.coli (Kane, 1995) were selected to ensure good lev-
els of expression. At the 5’ end of the gene an EcoRI restriction
site was added and at the 3’ end two stop codons and a HindIII
restriction site were included in order to make a direct cloning
into pUC 18 (cloning vector) and pASK 40 (expression vector)
possible. New restriction sites were introduced without alter-
ation of the amino acid sequence. Unique sites already present
in the DNA sequence were left undisrupted and repeated sites
were eliminated to allow cassette mutagenesis. Synthesis was
basically performed according to (Khorana, 1979; Ferretti et al.,
1986). The gene was divided into 12 oligonucleotides, which
were purchased from MWG-Biotech (Ebersberg, Germany).
Briefly, 200 pmol of the internal oligonucleotides
(SBwt-02, -03, -04, -05, -06, -07, -08, -09, -10, -11) were phos-
phorylated at their 5’ ends. After phosphorylation, the internal
oligonucleotides were mixed with 200 pmol of the external
oligonucleotides (SBwt-01 and -12). This hybridisation mixture
was incubated at 95 °C during 5min and cooled down overnight
to room temperature. The internal nicks were subsequently lig-
ated and the hybridisation product was purified by elec-
trophoretic separation on a 2% low melting agarose gel. The
DNA fragment was extracted from the gel and ligated in a molar
ratio of 15:1 into a pUC 18 cloning vector previously digested
with EcoRI and HindIII. Correct plasmids were selected after re-
striction analysis and DNA sequencing. The hybrid SBsc3-KD2
was synthesised in the same way as stefin B, replacing the oli-
gos SBwt-09 and -10 by SBsc3-09 (5’-TGCGTGTTTTCC-
AGGACATCCAGCTGCGTATCGCTTCCAA-3’) and SBsc3 – 10
(5’-AAGGTCCTGTAGGTCGACGCATAGCGAAGGTTGATGTCT-
3’). SBsc1-KD2 and SBsc1/3-KD2 were obtained by cassette





ing the sequence corresponding to the N-terminus of KD2 was
ligated into the plasmids containing the correct sequences for
stefin B and SBsc3-KD2 after removing the original cassette by
EcoRI/PstI restriction digestion. For periplasmic expression in
E. coli, the genes obtained by synthesis or by cassette mutage-
nesis were subcloned into pASK40 (Skerra et al., 1991) via the
EcoRI/HindIII restriction sites. Recombinant strains, obtained by
transformation of JM 83 E. coli competent cells with the plas-
mids carrying the correct sequences of stefin B and stefin B-KD2
hybrids were cultured at 37 °C until OD550 nm = 0.6 – 0.8 and in-
duced, for heterologous expression, with 1 mM IPTG. The cells
were grown 4 hours at 30 °C and harvested by centrifugation
(4000 g, 25 min). Cell lysates were tested for expression by
SDS-PAGE and Western blot analysis using polyclonal antibod-
ies (rabbit) against human stefin B (DR Laboratories, Dießen) and
POD-anti rabbit IgG (goat; Dianova, Hamburg).
Isolation and Purification of the Recombinant Hybrids
Periplasmic fractions were isolated according to (Dalböge et al.,
1989) using a cold osmotic shock. Briefly, harvested cell pellets
were washed with 1/5 of the culture volume of chilled 200 mM
Tris/HCl, 20% sucrose, 100 mM EDTA (pH 9.0) and were shaken
on ice for about 10 min. After centrifugation at 6000 g for 20min,
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the pellets were resuspended in 1/5 of the culture volume of
chilled 20 mM Tris/HCl (pH 7.5). Purification of the hybrids was
achieved by affinity chromatography on a carboxymethyl-pa-
pain Sepharose column (Anastasi et al., 1983) followed by anion
exchange chromatography on a Mono Q column using a FPLC
system. 
SDS-PAGE, HPLC, N-Terminal Amino Acid Sequencing and
Mass Spectrometry
SDS-PAGE of the recombinant hybrids was performed in 15%
polyacrylamide gels according to Laemmli (1970). The homo-
geneity of the purified hybrids was checked by reversed-phase
HPLC. Two nmol of each sample were applied to a Jupiter
C4-column (150 x 1 mm, Phänomenix, Aschaffenburg, Ger-
many) and eluted with a linear gradient (0– 60%) of acetonitrile in
0.1% TFA using a flow rate of 60 m l×min– 1. The recombinant in-
hibitors were identified by N-terminal amino acid sequencing
with a gas-phase sequenator 473A (Applied Biosystems, Weiter-
stadt, Germany) according to the instructions of the manufactur-
er. The molecular masses of the inhibitors were determined by
mass spectrometry using a tandem quadrupole ionspray mass
spectrometer API III (Sciex Thornhill, Ontario, Canada) basically
as described elsewhere (Covey et al., 1988; Mann et al., 1989).
Inhibition Assays and Determination of Kinetic Constants
Inhibition of papain and cathepsin L was assayed at 30 °C and
pH 5.5 with the fluorogenic substrate Z-Phe-Arg-NH-Mec as de-
scribed in detail elsewhere (Machleidt et al., 1993, 1995). Inhibi-
tion of m -calpain (5 – 10 nM) was measured in continuous fluori-
metric assays at 12 °C (to slow down inactivation due to
autolysis) in 50 mM Tris/HCl, pH 7.5, 100 mM NaCl, 0.015% Brij-
35, 100– 150 m M CaCl2, and 1mM dithiothreitol (freshly added) in
a total volume of 500 m l using the fluorogenic substrate Suc-Leu-
Tyr-AMC (250 m M). After a constant reaction rate was achieved
(10 – 20 min), the inhibitors were added and the reaction was fol-
lowed towards a stable equilibrium (15 – 90 min). The rate con-
stants kon and koff for complex formation of cathepsin L, papain
and calpain with L-kininogen, kininogen domain 2 and the hy-
brids were obtained by presteady-state analysis of the progress
curves (Morrison, 1982). Equilibrium dissociation constants (Ki)
were calculated from the rate constants (Ki = koff/kon) or, for some
calpain inhibitors with very low affinity, measured directly in
steady-state experiments, and were corrected for competition
of the inhibitor with the substrate. The inhibitorily active concen-
trations of inhibitors were determined by titration with E-64-
standardised papain (4 nM) using the substrate Bz-R-NH-Mec
(10 m M) (Barrett and Kirschke, 1981). 
Isolation of m-Calpain from Human Erythrocytes
Human m -calpain (EC 3.4.22.17) was isolated from erythrocytes
following a protocol established in our laboratory (D. Gabrijelcic-
Geiger and E. A. Auerswald, unpublished). Briefly, after lysis of
erythrocytes and centrifugation, the supernatant was applied to
a DEAE-Sepharose ion-exchange column. Bound fractions were
eluted and further purified on Phenyl-Sepharose (separation of
calpastatin from calpain). Enzymatically active fractions were
applied to gel filtration on Superdex-200 and finally purified on
Blue-Sepharose. The final product was homogeneous (80 kDa
and 30 kDa subunits) and more than 95% pure as judged by
SDS-PAGE and N-terminal sequence analysis. Average yields
were about 2 mg of purified m -calpain from 600 ml erythrocyte
concentrate.
Cloning, Expression and Purification of a 21 kDa Calpain
Small Subunit Fragment
A C-terminal fragment (21 kDa) comprising residues 86 – 268
(preceded by Met) was created by cloning the PCR product of
the cDNA of the calpain 30 kDa subunit (kindly provided by K.
Suzuki (Institute of Molecular and Cellular Bioscience, Universi-
ty of Tokyo, Japan) into a pET-22b(+) vector. Expression was
achieved under the control of the T7 promotor in E. coli BL384,
rendering yields of about 15 mg/l cell culture. The recombinant
21 kDa protein carrying a C-terminal His6-Tag was isolated from
the soluble fraction of cell lysates and purified by affinity chro-
matography on a Ni-NTA column. This procedure provided a
>90% pure protein according to SDS-PAGE, N-terminal se-
quencing and mass spectrometry.
Biomolecular Interaction Analysis
Real-time biomolecular interaction analysis was performed us-
ing surface plasmon resonance technology in a BIAcore 2000
instrument (Biacore AB). The inhibitors were immobilised on
CM5 chips via amine group coupling. After activation of the sen-
sor chips with 35 m l 0.05 M N-hydroxysuccinimide and
0.2 M N-ethyl-N-[3-(diethylamino)propyl]carbodiimide (flow rate
5 m l×min– 1), 35 m l of the inhibitor solutions (25 – 100 m g×ml– 1 in
10 mM sodium acetate, pH 4.2) were injected, followed by 35 m l
of 1.0 M ethanolamine (pH 8.5) for deactivation of unreacted
groups. HBS buffer (Biacore) was used as running buffer
throughout the coupling procedure. After coupling, the chip was
washed with 3.0 M NaCl, 0.1 M NaOH to remove non-covalently
bound ligands. Binding experiments were performed at 25 °C in
50 mM Tris/HCl, 100mM NaCl, 0.015%Brij35, pH7.5, as running
buffer by injecting the analyte solutions (5– 100 m g ×ml– 1) over
10min with a flow rate of 5 m l×min– 1. The surface was regenerat-
ed between cycles by injecting 25 m l of 3.0 M NaCl, 0.1 M NaOH.
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